- 询价
- 辰辉创聚生物
- 中国
- NBAB-139512
- 2025年07月11日
- Flow Cytometry
企业认证
相关产品推荐更多 >
Vaspin Polyclonal Antibody抗体 | Anti-Vaspin Polyclonal Antibody
询价
抗Raf-1 (Phospho Ser338)单抗 | Anti-Raf-1 (Phospho Ser338) Monoclonal Antibody
询价
BCAM单抗 | Recombinant Anti-BCAM Monoclonal Antibody
询价
抗Human CSF1/M-CSF抗体 | Anti-Human CSF1/M-CSF Antibody
询价
CD8 alpha单抗 | Recombinant Anti-CD8 alpha Monoclonal Antibody
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Swine Lymphocyte protein
- 形态：
liquid
- 保存条件：
Short term 4℃; Long term -20℃.
- 保质期：
见COA
- 库存：
大量
- 供应商：
辰辉创聚生物
- 应用范围：
Flow Cytometry
- 靶点：
Swine Lymphocyte
- 抗体英文名：
Anti-Swine Lymphocyte Monoclonal Antibody
- 抗体名：
Swine Lymphocyte antibody
- 规格：
100ul; 500ul; 1ml
| 产品信息
品名:NebuSelect™ Anti-Swine Lymphocyte Monoclonal Antibody
货号:NBAB-139512
品牌:Nebulabio
规格:100ul; 500ul; 1ml
| 产品描述
| 产品属性
Product Category：Mouse MAb
Reactivity：Swine
Specificity：Swine Lymphocyte
Immunogen：Recombinant Swine Lymphocyte protein
Isotype：Monoclonal mouse IgG
Purification：Protein A & Antigen Affinity Purification
Buffer：0.2 μm filtered solution in PBS, pH7.4, containing 0.09% Sodium azide, 50% glycerol.
Conjugate：Unconjugated
Applications：Flow Cytometry
Dilution：FC 1:20～1:200
Storage：Store at 4°C for short-term, -20°C for long-term. Avoid repeated freezing and thawing cycles.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Production of Monoclonal Antibodies in Swine
A major objective of this laboratory has been to improve the growth performance of swine with immunological manipulation. During the progress of the program, we demonstrated that a mouse monoclonal antibody (MAb) was able to enhance
-phosphoserine的抗体。 摘抄： Anti-Phosphothreonine (MAb) - CryptateThe anti-phosphothreonine antibody is a monoclonal antibody (clone 42H4) produced at Cell Signaling Technology (reference 9386). It recognizes phosphorylated threonine residues in a manner
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
